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Angela Koutsokera1,3*, Konstantinos Kostikas2, Laurent P Nicod1 and Jean-William Fitting1Abstract
Exacerbations of COPD (ECOPD) represent a major burden for patients and health care systems. Innovative
sampling techniques have led to the identification of several pulmonary biomarkers. Although some molecules are
promising, their usefulness in clinical practice is not yet established. Medline and Highwire databases were used to
identify studies evaluating pulmonary sampled biomarkers in ECOPD. We combined 3 terms for ECOPD, 3 for
biomarkers and 6 for the sampling method. Seventy-nine studies were considered eligible for inclusion in the
review and were analyzed further. Pulmonary biomarkers sampled with non-invasive, semi-invasive and invasive
methods were evaluated for their potential to illustrate the disease’s clinical course, to correlate to clinical variables
and to predict clinical outcomes, ECOPD etiology and response to treatment. According to published data several
pulmonary biomarkers assessed in ECOPD have the potential to illustrate the natural history of disease through the
modification of their levels. Among the clinically relevant molecules, those that have been studied the most and
appear to be promising are spontaneous and induced sputum biomarkers for reflecting clinical severity and
symptomatic recovery, as well as for directing towards an etiological diagnosis. Current evidence on the clinical
usefulness of exhaled breath condensate and bronchoalveolar lavage biomarkers in ECOPD is limited. In conclusion,
pulmonary biomarkers have the potential to provide information on the mechanisms underlying ECOPD, and
several correlate with clinical variables and outcomes. However, on the basis of published evidence, no single
molecule is adequately validated for wide clinical use. Clinical trials that incorporate biomarkers in decisional
algorithms are required.
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The natural history of chronic obstructive pulmonary
disease (COPD) is marked by episodes of deterioration,
called exacerbations of COPD (ECOPD) which lead to
increased morbidity and mortality [1]. An ERS/ATS Task
Force published in 2008 has described ECOPD as one of
the clinical outcomes of COPD that should be used for
the assessment of patients and for defining the impact of
treatment interventions [2]. In addition to the functional
and imaging markers, increasing evidence suggests
that sampling, either local or systemic, of biological* Correspondence: angela.koutsokera@chuv.ch
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distribution, and reproduction in any mediummolecules known as biomarkers can provide an insight
in the pathophysiological mechanisms of ECOPD [2,3].
Sampling methods elaborated during the last decades
offer an innovative basis for the identification of pul-
monary biomarkers. These techniques may be totally
noninvasive [e.g. exhaled air, exhaled breath condensate
(EBC), spontaneous sputum (SS)], semi-invasive (e.g. in-
duced sputum (IS), nasal wash, large airways’ secretions)
or invasive [e.g. bronchoalveolar lavage (BAL), lung bi-
opsies]. Although readily implemented in the research
laboratory, their wide application has long been ham-
pered by the lack of standardization and the absence of
reference values, issues that are being increasingly
addressed in the literature [4,5]. The aim of this system-
atic review is to provide an overview of the pulmonary
sampled biomarkers studied in the context of ECOPDtral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in an attempt to illustrate the potential clinical implica-
tions of current evidence.Methodology and definitions
A search for articles, published in the English language
until April 2013, was conducted using Medline and
Highwire databases as well as the reference lists of re-
trieved publications. Studies were considered pertinent if
they evaluated non-systemic, pulmonary sampled bio-
logical molecules in the context of ECOPD. Research
included – but was not limited to - 3 keywords for
ECOPD (COPD exacerbation, COPD deterioration,
acute COPD), 3 for biomarkers (biomarkers, cytokines,
oxidative stress) and 6 for the sampling methods (ex-
haled, EBC, BAL, IS, SP, lung biopsies). Abstracts or un-
published reports were not included in the current
review, whereas data obtained from mixed populations
were excluded from further analysis. Data on cellular,
functional or imaging parameters that may be used as
markers of disease were not included in the present
review. Biomarkers sampled with non-invasive, semi-
invasive or invasive methods were evaluated for their po-
tential: 1) to illustrate the natural history of ECOPD
through the modification of their levels, 2) to correlate
with clinical variables [e.g. symptoms, clinical severity,
pulmonary function tests (PFTs) and arterial blood gas
(ABG)] and 3) to serve as predictors of clinical outcomes
(e.g. recovery, length of hospital stay and ECOPD fre-
quency), ECOPD etiology and response to treatment.
The methodology used was in accordance with the
PRISMA guidelines [6]. A flow chart diagram of the
search strategy and study selection is provided in
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Figure 1 Flow chart diagram of the search strategy and study selectioAs described previously for systemic biomarkers in
ECOPD [7] the following terminology was applied
invariably:
 ‘Baseline’ refers to a time-point of clinical stability,
before the development of ECOPD (used for
longitudinal studies).
 ‘ECOPD onset’ refers to the first time-point at
which ECOPD patients were assessed by the
investigators.
 The terms ‘stability or recovery’ were avoided and
the specific time point of assessment was preferably
used.
 ‘Stable COPD’ refers to cross-sectional studies
comparing ECOPD patients with another group of
COPD patients.
Results and discussion
Non-invasive sampling
Exhaled biomarkers
Breath analysis is considered to be a valuable non-
invasive technique for sampling volatile biomarkers.
With the exception of one study which assessed four
volatile biomarkers simultaneously [8], fractional exhaled
nitric oxide (FeNO) is the only exhaled biomarker stud-
ied in ECOPD (Table 1). Electronic nose, a recently de-
veloped omics technique that provides a ‘breathprint’ of
exhaled volatile organic compounds, has not been stud-
ied yet during ECOPD [9].
Although, in stable COPD FeNO is derived predomin-
antly from the periphery of the lung [19], in ECOPD it
appears to be produced homogeneously in the central
and peripheral airways [10]. FeNO at ECOPD onset is
characterized by a wide range of concentrations and ini-
tially elevated levels as compared to controls have nots excluded on the basis of the publication type
s, letters, editorials, abstracts) (n=51)
 excluded on the basis of the sampling method: 
ssment of systemic biomarkers (n=53)
vo studies (n=8)
s excluded on the basis of the selected
ation: 
e COPD, without assessment of ECOPD-related
es (n=32)
ion of studies using mixed ECOPD populations :
r respiratory tract infections (n=2)
onary infiltrates (n=1)
chiectasis (n=1)
 respiratory failure (n=1)
ble COPD including both ECOPD and severe 
 (n=1)
n.
Table 1 Assessment of FeNO in ECOPD
Ref. Course: At ECOPD onset Course: Comment
From Baseline to
ECOPD Onset
FeNO levels
(ppb)
Comparisons After ECOPD
onset
Agusti et al. [10] €41.0 ± 5.1,
† 5.7-76.5
ECOPD > controls ↓ GCS. ↓ by M1-2 or by M6-8
Al-Ali et al. [11] £10.3 (2.7-34) ↔ECOPD, controls, pneumonia
↔ECOPD smokers, ex smokers
Antus et al. [12] ¥25.3 (21.2–30.1) ↓ GCS. ↓ by discharge
Antus et al. [13] ¥23.8 (19.4–29.7) ↔ECOPD smokers, ex smokers ↓ ↓ by discharge
Bhowmik et al. [14] ↑* #7.40 (4.80–9.60) ↓* Exact time points N/R
Cosio et al. [15] N/R ↓ GCS. ↓ by M3
Kersul et al. [16] N/R N/R ↓ GCS. ↓ by M3 after discharge
Lazar et al. [17] ‡10 (7) ↔ECOPD, controls (non-smokers,
smokers)
N/R Time points: admission,
discharge
Papi et al. [18] €15.18 ±1.85 ↓ GCS. ↓ by W8-10
The columns concerning the course of FeNO refer to longitudinal studies (paired samples) and the column concerning comparisons at ECOPD onset refers to
cross-sectional studies (unpaired samples).
Abbreviations: D day after ECOPD onset, FeNO fraction of exhaled nitric oxide, GCS administration of systemic glucocorticosteroids, M months after ECOPD
onset, N/R not reported, ppb parts per billion, W weeks after ECOPD onset.
Symbols:↔: no difference, ↑: increase, ↓: decrease, € mean ± SEM, † range, £ median (range), ¥ geometric mean (95% CI), # Median (interquartile range), ‡ mean
(SD), *: stability samples obtained before and after the ECOPD.
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uniformity may be attributed to different study designs
and confounding factors, such as smoking or inhaled
corticosteroids (ICS), which are known to influence
FeNO levels [20]. Despite the wide range of initial con-
centrations, most studies report a reduction of FeNO
during follow-up [10,12-16,18].
FeNO was associated with the presence of a sore throat
[14] and during viral ECOPD its levels correlated with spu-
tum eosinophils [18]. Although, a correlation with PFTs has
not been invariably demonstrated [10,13], in the study of
Antus and coworkers, FeNO on admission correlated posi-
tively with post-treatment increases in FEV1, and the de-
crease of FeNO correlated with the increases in FEV1. In
this study, FeNO on admission was a predictor of a signifi-
cant post-treatment increase in FEV1 with an optimum
cut-off point of 26.8 ppb. For this threshold sensitivity was
74%, specificity was 75% and positive and negative predict-
ive values were 60 and 85% respectively [12]. ABG parame-
ters did not correlate significantly with FeNO levels [13].
Concerning clinical outcomes, a weak inverse correlation
has been reported between FeNO on admission and the
length of hospital stay [12]. Finally, in regard to therapeutic
interventions, intravenous glucocorticosteroids (GCS) failed
to acutely reduce FeNO levels in ECOPD patients [10]
whereas the co-administration of theophylline was not
accompanied by an additional reduction of FeNO [15].
Exhaled breath condensate
Exhaled breath is saturated with water vapor which can
be condensed by cooling and used to sample a widerange of mediators. EBC samples the entire respiratory
tract but newer techniques allow fractionated sampling
and provide the ability to collect condensate from differ-
ent parts of the respiratory tract [21,22]. EBC collection
is a promising sampling method but several methodo-
logical issues hamper its clinical use [4,5]. In the context
of ECOPD, detection rates of some of the sampled bio-
markers, notably cytokines, have been particularly low
[23,24] whereas for inflammatory mediators of a peptide
nature, better detection rates have been achieved with
albumin-coated sampling devices [23]. Studies compar-
ing EBC, sputum or BAL in the context of ECOPD are
scarce [24-26].
Only a few studies have focused on EBC biomarkers of
ECOPD (Table 2) and so far no study has assessed the
course of biomarkers between baseline and the onset of
ECOPD. EBC pH, one of the most validated EBC bio-
markers, has been assessed only by one study which
found no correlations with PFTs and ABG parameters
[13]. NO-related products have not yet been evaluated
in this context, whereas for hydrogen peroxide (H2O2)
published data showed correlations with dyspnea but no
correlations with the clinical status or the PFTs [27-29].
Isoprostanes and leukotrienes, are arachidonic acid
metabolites that have also been measured in EBC sam-
ples. So far no double-blind placebo-controlled trial has
focused on the effect of treatment interventions on EBC
biomarkers. Definite conclusions cannot be drawn based
on published evidence, but it has been shown that levels
of 8-isoprostane were elevated and fell significantly
after treatment, decreasing further in subjects receiving
Table 2 Assessment of EBC biomarkers at ECOPD
Biomarker Ref. ECOPD onset Course: Comment
Comparisons After ECOPD
onset
AAT [30] ECOPD > COPD, controls
ATP [17] ↔: ECOPD, smokers, non-smokers ↔ Time points: admission, discharge
cysLTs [29] ↓ ICS with or without systemic GCS. Time points: onset,
Visit 1 (D2-4), Visit 2 (2-4D post antibiotics),
Visit 3 (21-28D post antibiotics). ↓ by visit 2.
H2O2 [27] ECOPD > controls (smokers and non-smokers) ↓ GCS. ↓ by D7
[28] ↓ GCS. ↓ by D3-4
[29] ↓ ICS with or without GCS. Time points: onset,
Visit 1 (D2-4), Visit 2 (2-4D post antibiotics),
Visit 3 (21-28D post antibiotics). ↓ by visit 2.
IL-1β [24] ECOPD > controls, smokers, stable COPD
IL-6 [31] ECOPD > controls ↓ No GCS. ↓ by 2 W. Reduced after 6 M of mucolytic
therapy
[24] ECOPD > controls, stable COPD,
ECOPD In GW > smokers
ICU or GW patients
IL-8 [24] ECOPD > controls, smokers, stable COPD ECOPD patients hospitalized either in the ICU or in GW
[32] Undetectable in most subjects
[25] ECOPD > nonsmokers, asymptomatic smokers,
symptomatic smokers
Detected in 14% of healthy smokers, 20% of
non-symptomatic smokers, 43% of symptomatic smokers
[33] ECOPD > asthma exacerbations,
↔: ECOPD, controls
GCS.
IL-10 [24] ECOPD > controls, smokers, stable COPD ICU or GW patients
IL-12p70 [24] ECOPD > controls, smokers, stable COPD ICU or GW patients
IL-17 [33] ↔: ECOPD, asthma exacerbations, controls GCS.
IFN-γ [23] ECOPD < controls (p value N/R) Improved detection when an albumin-coated collector
was used
8-
isoprostane
[31] ECOPD > controls ↓ No GCS. ↓ by 2 W. Reduced after 6 M of mucolytic
therapy
[34] ECOPD > controls ↓ No GCS. ↓ by 2 W. Reduced further within 2 M
[25] ECOPD > nonsmokers,
asymptomatic smokers,
Symptomatic smokers
[29] ↓ ICS with or without systemic GCS. Time points: onset,
Visit 1 (D2-4), Visit 2 (2-4D post antibiotics),
Visit 3 (21-28D post antibiotics). ↓ by visit 2.
LTB4 [34] ECOPD > controls ↓ No GCS. ↓ by 2 W. Reduced further within 2 M
[32] ↔: ECOPD, controls, stable COPD ↔ GCS. Time points: D5,14,30,60
[29] ↓ ICS with or without systemic GCS. Time points: onset,
Visit 1 (D2-4), Visit 2 (2-4D post antibiotics),
Visit 3 (21-28D post antibiotics). ↓ by visit 3.
MPO [23] ECOPD > controls For samples collected with an albumin-coated apparatus
Ph [13] ↔: ECOPD, controls ↔ Time points: admission, discharge. CO2 standardization
method
PGE2 [29] ↔ ICS with or without systemic GCS. Time points: onset,
Visit 1 (D2-4), Visit 2 (2-4D post antibiotics),
Visit 3 (21-28D post antibiotics).
Protein [24] ↔: ECOPD, controls, smokers, stable COPD
[35]
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Table 2 Assessment of EBC biomarkers at ECOPD (Continued)
SLPI [23] ECOPD > controls For samples collected with an albumin-coated apparatus
TNF-α [24] ECOPD > controls, smokers, stable COPD ICU or GW patients
[32] ↔: ECOPD on D5, controls, stable COPD ↑ GCS. Time points: D5, 14, 30, 60. Lowest levels on D5,
D14 > D5 and D14 = D30 = D60
[33] ↔: ECOPD, controls GCS.
The column concerning the course of EBC biomarkers refers to longitudinal studies (paired samples) and the column concerning comparisons at ECOPD onset
refers to cross-sectional studies (unpaired samples). No study has assessed the course of EBC biomarkers from baseline towards ECOPD onset.
Abbreviations: AΑΤ alpha 1 antitrypsin, ATP adenosine triphosphate, CysLTs cysteinyl-leukotrienes, D day after ECOPD onset, GCS administration of systemic
glucocorticosteroids, GW general ward, H2O2 hydrogen peroxide, ICS inhaled corticosteroids, ICU Intensive care unit, IL interleukin, IFN-γ interferon gamma,
LTB4 leukotriene B4, M months after ECOPD onset, min: minimum, MPO myeloperoxidase, N/R not reported, PGE2 prostaglandin E2, SLPI secretory leukocyte
protease inhibitor, TNF-α tumor necrosis factor alpha, W weeks after ECOPD onset.
Symbols:↔: no difference, ↑: increase, ↓: decrease.
Koutsokera et al. Respiratory Research 2013, 14:111 Page 5 of 12
http://respiratory-research.com/content/14/1/111mucolytics for 6-months. Data concerning the effect of
GCS and antibiotics on the levels of Leukotriene B4
(LTB4) are controversial [29,34,36].
Despite the abovementioned problems of traceability,
pulmonary sampled cytokines have been extensively
studied in the context of ECOPD. Of interest is the ra-
ther distinct pattern of TNF-α whose levels at day 5 are
lower than those at day 14 [32]. This evolution pattern
has also been described for systemic TNF-α and could
provide evidence of a sustained inflammatory reaction
during the late recovery period [37]. Concerning clinical
variables, IL-8 at ECOPD onset correlated inversely with
PFTs [25] whereas in regard to treatment interventions,
clinical interpretation of published data should be done
with caution in the absence of double-blind placebo-
controlled trials. Small statistically significant differences
in the concentrations of IL-6 have been observed after a
2 week antibiotic treatment and were followed by a fur-
ther reduction after a 6-month course of mucolytics
[31]. Interestingly, TNF-α levels at ECOPD onset did not
differ according to the use of ICS [24], but at day 60 post
hospitalization lower TNF-α levels have been found in
patients on ICS therapy [32].
Spontaneous sputum
Most of the SS biomarkers studied during ECOPD
(Additional file 1: Table S1 and S2) were evaluated for
their associations with the clinical severity and the
causal diagnosis. Neutrophil elastase (NE) and some
antimicrobial peptides correlated with clinical severity
scores [38-40], whereas the magnitude of IL-8 rise from
baseline correlated with symptom recovery time [41]. Per-
sistent symptoms were paralleled by persistently elevated
levels of IL-8, TNF-α and NE, and clinical resolution was
related to their decrease to pre-ECOPD levels [39].
Sputum purulence has long been used for therapeutic
decisions [42] but its association with the microbiologic
yield has been controversial [43-45]. Published studies
report that in ECOPD sputum myeloperoxidase (MPO)
and IL-8 are associated with sputum color and puru-
lence [44]. Moreover, MPO has been associated with thesputum leucocyte count [46], IL-8 with sputum bacterial
load and the polymorphonuclear macrophages count [46],
whereas the log of LTB4 concentration has been associ-
ated with the overall chemotactic activity of sputum [47].
As far as specific pathogens are concerned, published
data are of particular interest. In a cohort of 50 patients
studied during 6 years, acquisition of H. influenza and
M.catarrhalis was associated with changes in SS levels
of antimicrobial peptides and distinct trends of change
were observed at ECOPD as compared to colonization
[40]. The study of Dal Negro et al. used a two stage lo-
gistic model to identify the cause of an ECOPD. At the
first decisional step, TNF-α enabled the recognition of
ECOPD associated with the presence of Ps.aeruginosa,
whereas at the second decisional step IL-8 and IL-1β
discriminated patients with bacterial causes from those
with a viral cause and from the non-infected ones
[48]. Another study, reported that, sputum NE levels of
350 mU/ml had a sensitivity of 70.6%, a specificity of
84.2%, a positive predictive value of 88.9% and a negative
predictive value of 61.5% in distinguishing H. influenza
or M.catarrhalis from non bacterial ECOPD [38]. In a
prospective study of the same group, TNF-α had the lar-
gest area under the curve for the identification of new
strain ECOPD whereas combinations of sputum TNF-α,
sputum NE and serum CRP performed better than any
single biomarker [39]. Finally, following treatment, the
decrease of IL-8, MPO, LTB4 and albumin leakage was
more substantial after bacterial eradication [49].
Semi-invasive sampling
Induced sputum
Sputum induction is used in clinical practice for micro-
biological and cell count studies, whereas measurement
of inflammatory biomarkers is increasingly implemented
in research. Methodological issues that may influence
the measurement of biomarkers, such as sample pre-
treatment with dithiothreitol, have been an issue of discus-
sion in the literature [50]. Two studies that evaluated the
safety profile of sputum induction during ECOPD support
the safety of its proper use in this setting [51,52].
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natants of induced sputum (Additional file 1: Table S1
and S2) but most of the groups studied cytokine levels,
notably IL-6, IL-8 and TNFα. As compared to stable
COPD or to baseline, IL-6 [53,54] and TNFa [55] levels
were increased at ECOPD onset but this was not invari-
ably observed for IL-8 [53-55]. During ECOPD, high
levels of IL-6 have been associated with the presence of
common cold symptoms [53] and a higher change from
baseline in IL-6 concentration has been associated with
a rhinovirus infection [54]. These findings were sup-
ported by a study evaluating an experimental virus
infection of COPD patients, in which peak viral load
correlated positively with peak sputum IL-6, IL-8, NE
and TNF-α as well as with peak serum CRP levels [56].
On the other hand, although data are partly controver-
sial [55,57], bacterial exacerbations were associated with
increased IL-6, IL-8, TNFα, LTB4 and MPO levels [57],
and TNFα was the best predictor of a bacterial ECOPD
when compared to CRP and induced sputum MPO [57].
During recovery, some studies described a reduction
of the levels of IL-6, IL-8 and TNFα under bronchodila-
tors and systemic GCS with or without antibiotics
[15,55], whereas other studies did not demonstrate a re-
duction of IL-6 and TNFα levels even 3 months after
hospital discharge [16]. The adjunction of theophylline
was associated with further reductions in IL-8 and
TNFα, suggesting that theophylline may potentially
enhance the anti-inflammatory action of standard
treatment, notably that of systemic GCS [15]. Finally,
budesonide and formoterol resulted in a significantly lar-
ger decrease in mRNA expression of IL-5 as compared
to placebo [58].
Spontaneous and induced sputum data analyzed
in conjunction
As illustrated before, sputum analysis has been an area of
intensive research. Sputum purulence and sputum cell
counts have been particularly promising and were studied
for their potential to characterize biological phenotypes
of ECOPD and predict response to treatment [59,60].
Differences in the etiology of ECOPD but also in the sever-
ity of COPD or in treatment may modify the inflammatory
response during ECOPD and notably the presence or not
of sputum eosinophilia [53,61]. Concerning the analysis of
biological molecules, several studies analyzed in conjunc-
tion data obtained from spontaneous and induced sputum
(Additional file 1: Table S1 and S2). Although, in ECOPD,
both sampling methods resulted in comparable microscopic
purulence, salivary contamination and rate of isolation of
major pathogens [62], studies comparing biomarkers
between the two methods are scarce [38]. As different
methodologies may be considered a confounding factor,
these data are discussed separately in this section.At ECOPD onset, the change in sputum IL-8 and IL-6
from baseline is inversely related to the baseline FEV1
indicating that patients with more severe COPD exhibit
greater rises in inflammation at ECOPD [63]. Moreover,
secretory leukocyte protease inhibitor (SLPI) correlates
inversely with sputum polymorphonuclear leukocytes,
and within the first 48 h of treatment a fall of the spu-
tum polymorphonuclear count by 70% is accompanied
by an increase in sputum SLPI and reductions of IL-8
and TNF-α [64].
In regard to the etiology of ECOPD, increased sputum
IL-8 and TNF-α was associated to bacterial infection
[64], whereas the rise of sputum IL-8 from baseline cor-
related with the rise in the airway bacterial load [63]. In
the study of Bafadhel and coworkers a panel of bio-
markers was evaluated in regard to four ECOPD pheno-
types (bacteria-predominant, virus-predominant, sputum
eosinophil-predominant and pauci-inflammatory exacer-
bations). These phenotypes could not be distinguished
according to Anthonisen’s criteria and no single bio-
marker had an area under the curve greater than 0.70 in
diagnosing an ECOPD. However, sputum IL-1b and
serum CRP performed better in determining bacteria-
associated ECOPD. For sputum IL-1b a cutoff point of
125 pg/ml had a sensitivity of 90% and a specificity of
80%, performing better than CRP [59].
Invasive sampling
Bronchoalveolar lavage
BAL obtained through bronchoscopy permits the study
of cellular and biochemical components present in the
epithelial lining fluid. So far only a few studies assessed
simultaneously BAL and other airway sampling tech-
niques in ECOPD [24,65,66]. Based on current evidence,
the clinical usefulness of BAL biomarkers in ECOPD is
rather limited. BAL biomarkers may illustrate the under-
lying mechanisms of ECOPD [24,65,67-70], but meth-
odological issues such as low sample numbers or sample
manipulation techniques have been considered to be
confounding factors limiting the statistical significance
of the results [24,65].
Biomarkers of bronchial biopsies obtained during ECOPD
Biomarkers expressed in biopsies obtained during
ECOPD (Additional file 1: Table S3) have been evalu-
ated principally for their potential to act as neutrophil
[71] or eosinophil [72-74] chemoattractants but associ-
ations with clinical variables or outcomes have not
been sufficiently assessed. In this regard, in patients
suffering from severe ECOPD, increased neutrophilia
has been associated with an upregulation of the gene
expression of two cytokines (epithelial-derived neutro-
phil attractant 78 and IL-8) and the expression of re-
ceptors CXCR1 and CXCR2. Although no association
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and the presence of a viral infection, subjects with
evidence of viral infection had fewer CXCR1 m-RNA
positive cells [71].
Insights from stable COPD sampling
Pulmonary biomarkers sampled during stable COPD
have been assessed for their potential to predict an
imminent ECOPD and to identify patients at risk for fre-
quent ECOPD (Table 3). Some molecules, such as FeNO
[75], exhaled volatile compounds [76], sputum MPO
[77] and BAL IL-8 [78], are promising but their clinical
usefulness is not yet established due to the lack of large
studies. BAL neutrophilia has been associated with an
increased frequency of ECOPD [79], whereas sputum
eosinophilia appears to be more promising than specific
biomarkers in identifying patients at risk for an ECOPD
[76,77], those that might benefit from the introduction
of ICS [80] and those who could actually stop ICS with-
out increasing the risk for an early exacerbation [77].
Promising biomarkers and future challenges
As in the case of systemic biomarkers in ECOPD [7],
several pulmonary biomarkers are promising but none
can be considered validated enough to gain its way into
everyday clinical practice. So far no single biomarker can
reliably identify an ECOPD at its onset, differentiate dif-
ferent gravities of ECOPD or consistently predict an un-
favorable outcome, but most of the studied biomarkers
have the potential to illustrate the clinical course of
disease through the modification of their levels and to
provide information on the underlying mechanisms of
disease. Some molecules correlate with clinical variables,
whereas a few may predict outcomes, direct toward a
causal diagnosis or provide information concerning the
response to treatment (Table 4). Pinpointing the most
promising biomarkers and highlighting some clinically
relevant conclusions, we may mention the following:
■ Although based on a single study, FeNO on
admission may predict a significant post-treatment
increase in FEV1. An optimum cut-off point of
26.8 ppb had a sensitivity of 74% and a specificity
of 75% [12].
■ Among sputum biomarkers, the following ones
appear more promising:
o Spontaneous sputum NE, IL-8 and TNF-a may
reflect clinical severity and symptomatic recovery
[38,39,41].
o Spontaneous sputum antimicrobial peptides
(lysozyme, LL37 and SLPI) were associated to the
acquisition of H. influenza and M. catarrhalis, and
distinct trends of change were observed at ECOPD as
compared to colonization [40].o Spontaneous sputum TNF-α, IL-8, NE and IL-1β as
well as induced sputum IL-6, IL-8, TNFα, LTB4 and
MPO directed towards an etiological diagnosis
[38,48,57,59,64]. Among induced sputum biomarkers
TNFα was the best predictor of a bacterial ECOPD
[57], whereas sputum IL-1b performed better than CRP
in determining bacteria-associated ECOPD [59].
o The decrease of spontaneous sputum IL-8, MPO,
LTB4 and albumin leakage was more substantial when
bacterial eradication was achieved [49].
■ IL-6 was associated with a rhinovirus infection both
in induced sputum [54,56] and in BAL [67].
■ Combinations of different pulmonary and/or
systemic biomarkers may perform better than
single biomarkers in identifying the causal etiology
of ECOPD [39,59].
■ Current evidence on the clinical usefulness of
exhaled breath condensate and BAL biomarkers in
ECOPD is limited.
■ Several biomarkers sampled during stable COPD
have the potential to identify patients at risk for
frequent ECOPD, whereas patients with more severe
COPD may exhibit greater rises in inflammation at
ECOPD [63].
As already illustrated, biomarker discovery has become
an area of intense investigation during the recent years.
Collaborative efforts to standardize the procedure of
biomarker development have identified 6 conceptual
steps (discovery, qualification, verification, research assay
optimization, biomarker validation and commercialization)
[3,88,89]. In this context, the STARD statement and its pro-
posed flowchart are useful resources that may improve the
diagnostic accuracy of studies [90]. As a general framework,
the aforementioned steps should also be implemented in
the study of ECOPD biomarkers, especially when innovat-
ing sampling techniques are used. Currently, the majority
of pulmonary biomarkers studied during ECOPD are at the
initial steps of discovery and qualification, whereas only a
limited number of studies have proceeded towards the sub-
sequent steps of biomarker validation. The most advanced
evaluation, so far, concerns the use of sputum biomarkers
for the etiological diagnosis of ECOPD but the methodo-
logical heterogeneity of the conducted studies renders gen-
eralized data interpretation challenging. In order to obtain
clinically applicable biomarkers, future studies should go
beyond the simplistic description of biomarker kinetics and
provide clinically oriented data. In parallel to the conduc-
tion of meticulous methodological studies, clinical decision
studies are needed. Modern sequencing techniques such as
metabolomics, proteomics or genomics are particularly
promising and may help identify phenotype specific bio-
markers. However, in complex diseases where redundant,
Table 3 Lung biomarkers measured during clinically stability (baseline) as predictors of ECOPD frequency
Sample Biomarker Ref. Comment
Exhaled air FeNO [81] ↔: frequent (≥3/year), infrequent (≤2/year) ECOPD
[75] Intra-individual FeNO variability is positively associated with the ECOPD frequency
eNOCoV≥ 40%: twofold increase in ECOPD rate as compared to COPD with eNOCoV <40%*
VOCs [76] Several compounds were associate with the number of ECOPD in the previous year
EBC pH [82] No significant correlation with ECOPD frequency over the following 6Μ
Spontaneous sputum Elastase [83] ↔: frequent (≥3/year), infrequent (≤2/year) ECOPD
IL-8 [83] ↔: frequent (≥3/year), infrequent (≤2/year) ECOPD
LTB4 [83] ↔: frequent (≥3/year), infrequent (≤2/year) ECOPD
MPO [83] ↔: frequent (≥3/year), infrequent (≤2/year) ECOPD
Protein
leakage
[83] ↔: frequent (≥3/year), infrequent (≤2/year) ECOPD
Induced sputum ECP [77] Not statistically significant hazard for ECOPD after cessation of ICS
IL-6 [53] Correlated with the frequency of ECOPD
IL-8 [84] Correlated with the total bacterial count. Bacterial colonization at baseline was associated with
ECOPD frequency
[53] Correlated with the frequency of ECOPD
LTB4 [77] Not statistically significant hazard for ECOPD after cessation of ICS
MPO [77] In the monovariate analysis (but not in the multivariate analysis) sputum MPO per neutrophil was a
significant hazard for ECOPD after cessation of ICS. MPO level per se were not a significant hazard.
SLPI [83] Negative correlation with ECOPD frequency over the preceding year
[84] Lower levels in samples colonized with a possible pathogen. Bacterial colonization in the stable
state was associated with increased frequency of ECOPD.
Induced and spontaneous
sputum
ET-1 [85] ET-1 at stability and the rise of ET-1 during ECOPD did not correlate with the frequency of ECOPD
IL-6 [86] Patients with frequent ECOPD (≥2.52/y) had a faster rise over time in sputum IL6
IL-8 [86] No significant relation to exacerbation frequency
Small volume lavage of the
large airways
Albumin [87] ↔: patients with ≥3 antibiotic treated ECOPD during the past 2 years, patients without recurrent
ECOPD
ECP [87] ↔: patients with ≥3 antibiotic treated ECOPD during the past 2 years, patients without recurrent
ECOPD
Hyaluronan [87] Not statistically significant difference in regard to recurrent ECOPD
IL-6 [87] ↔: patients with ≥3 antibiotic treated ECOPD during the past 2 years, patients without recurrent
ECOPD
IL-8 [87] ↔: patients with ≥3 antibiotic treated ECOPD during the past 2 years, patients without recurrent
ECOPD
MPO [87] ↔: patients with ≥3 antibiotic treated ECOPD during the past 2 years, patients without recurrent
ECOPD
Tryptase [87] ↔: patients with ≥3 antibiotic treated ECOPD during the past 2 years, patients without recurrent
ECOPD
BAL MPO [78] ↔: frequent (≥3/year), infrequent (<3/year) ECOPD
IL-8 [78] Higher levels in patients with frequent ECOPD, 1 pg/ml increase in IL-8 was associated with 1fold
increase in the risk of frequent ECOPD
NE [78] ↔: frequent (≥3/year), infrequent (<3/year) ECOPD
TNF-α [78] ↔: frequent (≥3/year), infrequent (<3/year) ECOPD
Data concerning mRNA expression of biomarkers were not included in this table.
Abbreviations: eNOCoV intra-individual FeNO coefficient of variation, ECP eosinophil cationic protein, ET-1 endothelin 1, FeNO exhaled nitric oxide, ICS inhaled
corticosteroids, IL interleukin, LTB4 leukotriene B4, MPO myeloperoxidase, NE neutrophil elastase, SLPI secretory leukoprotease inhibitor, TNFα tumor necrosis factor alpha,
VOCs: volatile organic compounds.
Symbols:↔: no difference.
*The FeNO monthly intra-subject variability was retrospectively assessed by calculating the CoV (mean/SD)x100.
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Table 4 Studies assessing biomarkers for their potential to provide clinically relevant information
Assessed biomarkers
Clinical variables
Symptoms at ECOPD onset FeNO[14], EBC: H2O2[28], IS: IL-6[53], Nasal wash: IL-6[46], IL-8[46]
Clinical severity EBC: CysLTs[29], H2O2[29], 8-isoprostane[29], LTB4[29], PGE2[29]
SS: lactoferrin[40], LL-37[40], lysozyme[40], NE[31,38], SLPI[40]
Large airway secretions: IL-8[65], TNF-α[65]
PFTs FeNO[10,12,13,20]
EBC: CysLTs[29], H2O2[29], 8-isoprostane[29], IL-8[25], LTB4[29], MPO[23], PGE2[29], pH[13], SLPI[23]
IS/SS: IL-6[63], IL-8[63]
ABG analysis FeNO[13]
EBC: pH[13]
Prediction of clinical outcomes
Symptomatic recovery SS: IL-8[39,41], NE[39], TNF-α[39]
Length of hospital stay FeNO[12]
Causal diagnosis FeNO[18]
SS: IL-1β[48], IL-8[38,46,48], LL37[40], lysozyme[40], ΝΕ[38,39], SLPI[40], TNFα[38,39,48]
IS: IL-6[54,56,57], IL-8[55-57], LTB4[57], MPO[55,57], NE[56], TNF-α[55-57]
IS/SS: IL-1β[59], IL-8[63,64], TNF-α[64]
NW: IL-6[46]
BAL: IL-6[68], IL-8[68], NE[68]
Response to treatment FeNO[10,15]
EBC: Cys-LTs[29], H2O2[29], IL-6[31], 8-isoprostane[29,31], LTB4[29], PGE2[29], TNFα[24,36]
IS: IL-8[15], TNFα[15,34,36]
Abbreviations: ABG arterial blood gas, BAL bronchoalveolar lavage, Cys-LTs cysteinyl-leukotrienes, EBC exhaled breath condensate, FeNO: fractional exhaled nitric
oxide, H2O2 hydrogen peroxide, IL interleukin, IS/SS induced and spontaneous sputum analyzed in conjunction, LTB4 leukotriene B4, MPO myeloperoxidase,
NE neutrophil elastase, PFTs pulmonary function tests, PGE2 prostaglandin E2, SLPI secretory leukoprotease inhibitor, SS spontaneous sputum, TNFα tumor
necrosis factor alpha.
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clear that the identification of clinically relevant biomarkers
will depend on our ability to integrate data from disparate
sources such as patient medical records and demographics.
In this context, data mining strategies and computational
models will be increasingly used for the extraction of clinic-
ally relevant information.
Conclusions
In the current review, we summarized the published
evidence regarding pulmonary biomarkers studied in the
context of ECOPD and attempted to highlight their
clinical relevance. Several biomarkers hold promise for
improving the understanding of the complex mecha-
nisms propagating ECOPD, several molecules correlate
with clinical variables and a few are associated with clin-
ical outcomes. Most of the evidence on the effect of
treatment is based on a limited number of open-label,
single-center studies that are characterized by a small
sample size and an undefined statistical power. Despite
these promising results, on the basis of the published
evidence, no single molecule can be proposed yet forwide use in clinical practice. Further experimental
studies and large scale clinical trials that incorporate
biomarkers in decisional algorithms are required.
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